0001209191-22-061898.txt : 20221219
0001209191-22-061898.hdr.sgml : 20221219
20221219162033
ACCESSION NUMBER: 0001209191-22-061898
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221215
FILED AS OF DATE: 20221219
DATE AS OF CHANGE: 20221219
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Seely Lynn
CENTRAL INDEX KEY: 0001327111
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40502
FILM NUMBER: 221471342
MAIL ADDRESS:
STREET 1: 501 2ND STREET
STREET 2: SUITE 211
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94107
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Lyell Immunopharma, Inc.
CENTRAL INDEX KEY: 0001806952
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 833006753
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 201 HASKINS WAY
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650 695-0677
MAIL ADDRESS:
STREET 1: 201 HASKINS WAY
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-12-15
0
0001806952
Lyell Immunopharma, Inc.
LYEL
0001327111
Seely Lynn
C/O LYELL IMMUNOPHARMA, INC.
201 HASKINS WAY
SOUTH SAN FRANCISCO
CA
94080
1
1
0
0
President and CEO
Option (right to buy)
3.28
2022-12-15
4
A
0
7500000
0.00
A
2032-12-14
Common Stock
7500000
7500000
D
Twenty-five (25) percent of the shares subject to the option shall vest on December 15, 2023 and 1/48th of the shares subject to the option shall vest in equal monthly installments thereafter until all shares are vested, subject to the reporting person remaining an employee of the Issuer on each applicable vesting date.
/s/ Charles Newton, as Attorney-in-Fact
2022-12-19